TET2 and myeloproliferative neoplasm: Inactivation of TET2 by genomic deletions or mutations has been reported in a wide range of adult hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN) [78-80], as well as in lymphoid malignancies [39,81] (Table 3).